Written by ι Stock Market Media Group Staff — June 6, 2013
Plandaí Biotechnology, Inc. (OTCQB: PLPL) recently put one of the company’s highly bioavailable products to work in a study to prove it can kill a deadly parasite. It was Plandaí’s Phytofare™ Catechin Complex, and it proved it can, in fact, be effective in killing the parasite. This is big news for a company that plans on using its products as an antimalarial drug target in the war on this worldwide disease that infects about 500 million people each year. Malaria is killing a staggering number of the people who do contract the disease. Of the 500 million infected, roughly 600 thousand of them will die.
Plandaí Biotechnology, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, plans to enter into Phase II human clinical trials using Phytofare™ with the eventual goal being FDA approval of an antimalarial drug. The recently announced results of the study will go a long way to getting Plandaí one step closer to submitting its application to the U.S. Food and Drug Administration requesting those human trials.
The study, conducted under the supervision of Dr. Sanjeev Krishna, a professor of molecular parasitology and medicine at St George’s London School of Medicine, showed proof in analytical tests that Plandaí’s Phytofare™ Catechin Complex was effective in killing the malaria parasite, plasmodium falciparum. Dr. Krishna developed the tests that were conducted at St George’s London School of Medicine at the Division of Cellular and Molecular Medicine, Centre for Infection.
In the study, the most dominant catechin, Epigallocatechin Gallate (EGCG) was isolated from Plandaí’s Phytofare™ extract and then had its effectiveness in killing the P. falciparum parasite compared against a purified EGCG extract. The results, which the company says are expected to be published soon, showed that the Phytofare™ extract killed the parasite and did so with a lower dosage than did the purified EGCG extract.
Roger Duffield, Chief Executive Officer of Plandaí Biotechnology, said of the results, “These initial findings provide evidence corroborating previous scientific findings that Epigallocatechin Gallate catechin can kill the malaria parasite. This study involving Phytofare™ is the first to show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial.”
The development of vaccine options has so far proven to be a challenge due to the complexity of the parasite. In addition, drug-resistant strains of the parasite are moving across Southeast Asia, prompting the need to develop a new line of drug options. Because of the results in the recent study of Plandaí’s product, there is reason to be confident that the company can be at the forefront of developing that new line of drug options.
Plandaí’s CEO said, “We believe these results validate our decade-long research into the opportunity for using botanical extracts as a means to combat one of the world’s great plagues. Dr. Krishna’s clinical data indicate that the Phytofare™ Complex has a stable platform with predictable outcomes, making it a suitable candidate for further investigations. We now have the opportunity to evaluate the extract in further studies, including inhibiting the parasite in the glucose transporter and as a potential prophylactic by destroying the sporozoites during their journey from injection into the human blood by the female mosquito to the liver.”
Plandaí says it is finalizing agreements to undertake further in vitro studies and studies in mice at the University of Cape Town’s Department of Clinical Pharmacology to further validate the antimalarial drug target through greater synergistic activity of the complete Phytofare™ catechin complex containing all eight catechins, rather than the single isolated Epigallocatechin Gallate (EGCG) used in the recent study.
Company officials say that once all of the results have been evaluated, the company will submit its application to the FDA to commence Phase II human clinical trials.